Save up -80% on Idelalisib

Note: this is a drug discount program, not an insurance plan.
RX BIN: 015558RX PCN: HTGroup ID: DDN6600Card Holder ID: DDN6600
Pharmacists and Patients support.

2019 Price of Zydelig

$10,42960 tablets/150mg
price without discount in nearest pharmacy. Price may vary.

Claim your free Idelalisib discount card

We offer free Zydelig coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Idelalisib every time. What are you waiting for? Claim your prescription drug card now!

Walgreens pharmacy
Walgreens pharmacy
CVS pharmacy
CVS pharmacy
Walmart pharmacy
Walmart pharmacy
Ride AID pharmacy
Ride AID pharmacy
CVS Target pharmacy
CVS Target pharmacy
Kroger pharmacy
Kroger pharmacy
rx

Get your Prescription

safe

It’s safe and free

pharmacy

Buy drugs in pharmacy

save money

Save money each time

Idelalisib volume of distribution

Idelalisib is highly (>84%) bound to plasma proteins, with a steady-state volume of distribution (Vd) of 23 L and a clearance of 14.9 L/h.

RX Prescription
Ask Your therapeut before taking any drugs.

About RX24Drugs

2018 Statistics

discount card

Discount Cards 16,000+

benefit

Clients Benefit 29%

savings

Total savings $4,735,080

What is Idelalisib

Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110 , the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110 and p110 , p110 is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.

Idelalisib mechanism of action

Idelalisib specifically inhibits P110 , the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110 and p110 , p110 is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.

Dosage forms of Idelalisib

DrugDosageQuantityPrice
Zydelig100mg60 tablets$10,430
Zydelig150mg60 tablets$10,429

Prescription Generics

false

International Brands

Zydelig

Synonyms

5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one

Manufacturers

Gilead Sciences Canada Inc

CAS number

870281-82-6

UNII

YG57I8T5M0

State

solid

Affected organisms

Humans and other mammals

Indication of Idelalisib

Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.

Toxicity of Idelalisib

In four studies of idelalisib with a total of 369 patients, 288 discontinued treatment; 150 (44%) withdrew due to adverse events, and 57 (15.4%) due to disease progression. Analysis of toxicity revealed a characteristic pattern, with grade 3 and 4 toxicities more common in less heavily pretreated patients and younger patients.

RX24 Drugs Disclaimer: consult your healthcare provider before buying a Idelalisib on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Idelalisib now!